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Cellular senescence, the irreversible proliferative arrest seen in somatic cells after a limited number of divisions, is considered a crucial
barrier to cancer, but direct evidence for this in vivo was lacking until recently. The best-known form of human cell senescence is
attributed to telomere shortening and a DNA-damage response through p53 and p21. There is also a more rapid form of
senescence, dependent on the p16-retinoblastoma pathway. p16 (CDKN2A) is a known melanoma susceptibility gene. Here, we use
retrovirally mediated gene transfer to confirm that the normal form of senescence in cultured human melanocytes involves p16, since
disruption of the p16/retinoblastoma pathway is required as well as telomerase activation for immortalisation. Expression
(immunostaining) patterns of senescence mediators and markers in melanocytic lesions provide strong evidence that cell senescence
occurs in benign melanocytic naevi (moles) in vivo and does not involve p53 or p21 upregulation, although p16 is widely expressed. In
comparison, dysplastic naevi and early (radial growth-phase, RGP) melanomas show less p16 and some p53 and p21 immunostaining.
All RGP melanomas expressed p21, suggesting areas of p53-mediated senescence, while most areas of advanced (vertical growth-
phase) melanomas lacked both p16 and p21, implying escape from both forms of senescence (immortalisation). Moreover, nuclear
p16 but not p21 expression can be induced in human melanocytes by oncogenic BRAF, as found in around 80% of naevi. We
conclude that cell senescence can form a barrier to melanoma development. This also provides a potential explanation of why p16 is
a melanoma suppressor gene.
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Cellular senescence, the growth arrest seen in normal mammalian
cells after a limited number of divisions, is controlled by key
tumour suppressors including p53 and p16, and is believed to be a
crucial barrier to tumour development (Sharpless and DePinho,
2004). However, evidence for this overall concept comes very
largely from cell cultures and animal models (Wynford-Thomas,
1999; Sherr, 2001; Sharpless and DePinho, 2004). No direct
evidence has yet been presented that cell senescence forms a true
barrier to development of human cancers in vivo, although
improved evidence from animal models has emerged recently
(Braig et al, 2005; Collado et al, 2005).
Two main pathways effecting normal cellular senescence in
culture have been reported. The best known form of senescence,
first described in fibroblasts, is effected primarily by the p53
pathway (Wynford-Thomas, 1999; Sherr, 2001; Sharpless and
DePinho, 2004), and can be overcome by expression of exogenous
hTERT (human telomerase reverse transcriptase, required for
telomere maintenance), to give immortal (indefinitely proliferating)
cultures (Bodnar et al, 1998). Here, senescence appears to be
dependent on limited shortening of telomeres, activating p53
through checkpoint kinases 2 and possibly 1 (CHK2 and CHK1)
(Stewart et al, 2003; d’Adda di Fagagna et al, 2003; Von Zglinicki
et al, 2005). An alternative route to senescence was reported in
certain epithelial cells. It involves only the p16/RB1 pathway, and
the cells require interference with this pathway as well as hTERT
expression, for immortalisation (Kiyono et al, 1998). p16-depen-
dent senescence was abolished by disruption of the RB1 pathway,
after which a further, p53-dependent growth arrest was observed.
p16-dependent arrest of epithelial cells was, however, circumvented
by culture with growth-inactivated fibroblast ‘feeder’ cells. The cells
showed extended proliferation, p53-dependent senescence, and
immortalisation with hTERT alone (Ramirez et al, 2001). The
authors suggested that p16-dependent senescence was an artefact of
imperfect culture conditions, leading to ‘stress’ (Ramirez et al,
2001).
In p16-dependent senescence, the cyclin-dependent kinase
(CDK) inhibitor p16 is synthesised and activates RB1, by inhibiting
phosphorylation of RB1 by CDK4 or CDK6 (Kiyono et al, 1998;
Sharpless and DePinho, 2004). p16 is itself a tumour suppressor;
germline mutations at its locus CDKN2A are principally associated
with familial melanoma in humans, with some increased incidence
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sof pancreatic cancer, suggesting particular importance in melano-
cytes (Gruis et al, 1995; Bennett, 2003; Hayward, 2003; Kefford
et al, 2004; Gray-Schopfer and Bennett, 2006). In sporadic cancers,
p16 alterations and deletions are more broadly distributed, being
found in many types of cancer. The COSMIC database of over
13000 cancer samples (Forbes et al, 2006) (http://www.sanger.
ac.uk/genetics/CGP/cosmic/) lists p16 point mutations in 15% of
all tested samples, including nearly every cancer type tested,
although the frequency varies with type and culture status (22% for
melanoma, 9% for all uncultured melanoma samples). This does
not include deletions, and a recent study by comparative genome
hybridisation highlighted p16 as the most commonly deleted gene
in uncultured primary melanomas, at 50% frequency (Curtin et al,
2005). Thus, at least 59% of uncultured melanomas apparently
have a p16 deficiency. To this can be added gene silencing;
CDKN2A promoter methylation was reported in 19% of invasive
primary melanomas (Straume et al, 2002). Moreover, a study with
melanoma cell lines found that 100% of lines with normal p16 had
a different alteration in the RB pathway (Bartkova et al, 1996). It is
not clear how many other cancer types show such high total
frequencies of somatic p16 alteration; but even if the specific
relation between p16 and melanoma is restricted to germline
mutations, it is interesting that there is evidence for the p16-
dependent form of senescence in human melanocytes, even in a
rich culture medium and with feeder cells (Bennett and Medrano,
2002; Sviderskaya et al, 2003). Two human melanocyte strains
lacking functional p16 both showed a greatly extended lifespan,
p53-dependent senescence, and immortalisation by hTERT alone
(Sviderskaya et al, 2003).
These findings suggested a parallel with melanocytic lesions.
Humans carrying p16 mutations have not only increased suscept-
ibility to melanoma, but usually also numerous melanocytic naevi
(moles), often large (Gruis et al, 1995; Bennett and Medrano, 2002;
Bennett, 2003), implying a role for p16 in limiting naevus growth
in these families. This led to surmises that moles may be
melanocyte clones that have proliferated following a first mutation,
then senesced (Bennett and Medrano, 2002; Mooi and Peeper,
2002; Bastian, 2003). Reports of activating BRAF mutations in most
melanomas (Davies et al, 2002) and around 80% of naevi (Pollock
et al, 2003) provided a likely candidate for the mutation that most
commonly initiates proliferation. BRAF is a protein serine/
threonine kinase that transduces mitogenic and other signals from
RAS to MAPK (Robinson and Cobb, 1997) and can regulate cell
proliferation. The most common oncogenic BRAF mutation in
melanomas, V600E (formerly called V599E), results in constitutive
ERK signalling in vivo and can transform immortal fibroblasts
(Davies et al, 2002) and immortal mouse melanocytes (Wellbrock
et al, 2004).
The senescence studies also suggested mechanisms for progres-
sion to melanoma. Malignant melanomas can originate in naevi,
sometimes through intermediate lesions (Clark et al, 1984; Herlyn
et al, 1985; Mooi, 1997; Hussein and Wood, 2002), as follows.
Dysplastic naevi tend to be large, with architectural irregularities
but not progressive growth, unlike melanoma (Mooi, 1997). Radial
growth phase (RGP) melanomas are thin, growing only in or near
the epidermis, while vertical growth phase (VGP) melanomas
invade more deeply and are competent for metastasis and
immortal in cell culture (Clark et al, 1984; Herlyn et al, 1985;
Clark, 1991). We proposed a genetic model, in which benign and
dysplastic naevi represent p16 and p53-dependent senescence,
while melanomas arise by immortalisation of melanocytes
(Bennett, 2003; Sviderskaya et al, 2003; Bennett, 2006). Published
biological and molecular data (Talve et al, 1997; Keller-Melchior
et al, 1998; Glaessl et al, 1999; Rudolph et al, 2000; Hussein and
Wood, 2002; Bennett, 2003; Sviderskaya et al, 2003) were
consistent with this model, but not conclusive, although a
convincing report of cell senescence in melanocytic naevi has
appeared recently (Michaloglou et al, 2005). We have now
identified the genetic requirements for immortalisation of human
melanocytes, and systematically studied molecular markers and
mediators of cell senescence in clinical pigmented lesions of
increasing malignancy. The results confirm that normal melano-
cyte senescence in culture is p16-dependent, show that the
senescence in benign pigmented naevi is not p53-dependent but
involves p16 expression, and support a key role for cell senescence
in melanoma suppression. We also confirm and extend another
finding of Michaloglou et al (2005) on senescence-like inhibition of
normal melanocyte growth by exogenous
V600EBRAF. This inhibi-
tion correlates with upregulation of p16, but not p21.
MATERIALS AND METHODS
Melanocyte culture and gene transfer
Primary human melanocyte strains Nohm1 (Bennett et al,
1985), 830c (Scott et al, 2002) and HM303CN (Minwalla et al,
2001) were grown as described (Bennett et al, 1985), except
in the following melanocyte medium (Sviderskaya et al, 2003):
RPMI 1640 medium, 10% foetal calf serum, 200nM
12-O-tetradecanoyl phorbol 13-acetate (Sigma Chemical Co.,
Poole, UK), 200pM cholera toxin (Sigma), 10ngml
 1 human
stem cell factor (R&D Systems, Abingdon, UK) and 10nM
endothelin 1 (Sigma), gassed with 10% CO2. Supplements shortly
after retroviral infection also included 1mM insulin, 40pM
fibroblast growth factor 2 (R&D Systems, Abingdon, UK)
and 1mgml
 1 a-tocopherol. Melanocytes for the BRAF studies
only were obtained from Cascade Biologics and were grown
in medium 254 with HMGS supplements (Cascade Biologics,
Mansfield, UK). WM266.4 melanoma cells (ATCC), all
producer cells and HeLa cells were grown in DMEM with 10%
calf serum. Retroviral gene transfer into melanocytes was largely
as described (Sviderskaya et al, 2003). All vectors, with or
without inserts, were from Dr CJ Jones (Pathology, University
of Wales College of Medicine, Cardiff, UK); the HPV16-E7 vector
was originally from D Galloway (Fred Hutchinson Cancer Research
Center, Seattle, WA, USA). pBABEpuro or pBABEneo vectors
were transfected into the Omega E ecotropic packaging line,
and supernatant containing virus used to infect jCRIP
amphotropic packaging cells (Danos and Mulligan, 1988). LXSN
vectors were grown in PA317 amphotropic packaging cells
(Halbert et al, 1991). jCRIP or PA317 medium containing
infectious virus was harvested (using appropriate containment
procedures) and frozen. Melanocytes were infected 1 day
after plating them at 4–5 104ml
 1. Supernatant was thawed,
filtered (0.45mm), supplemented with polybrene (3.5mgml
 1),
and incubated overnight with melanocytes. Conditioned
medium from the melanocytes before infection was then replaced.
Normal culture was resumed after 2–3 days. For infection
with a second vector, the procedure was repeated 2 weeks later.
Inserts included hTERT cDNA (Geron Corp., Menlo Park,
CA, USA) in pBABEpuro and HPV16-E7 in LXSN, as described
before (Halbert et al, 1991; Sviderskaya et al, 2003). The
p16 antisense vector contained p16 exon 1a cloned in the
antisense orientation between the BamH1 and EcoR1 sites of
pBABEneo and expressed from the viral LTR. Normal human
CDK4 cDNA was likewise expressed from the viral LTR
of pBABEneo. Some melanocyte cultures following infection
were plated on XB2 keratinocyte feeder cells (3 10
4ml
 1)
(Sviderskaya et al, 2003).
Transient transfection was by Nucleofectort technology, using
the manufacturer’s protocols (Amaxa GmbH, Cologne, Germany).
5 10
5 melanocytes were transfected with 5mg DNA of Myc-tagged
pEFm vector containing either no insert, wild-type or human
V600EBRAF sequences, and cultured in 1ml normal medium in a
well of a six-well plate for 5 days before assays.
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Two near-confluent cultures were each counted in triplicate by
haemocytometer, pooled and replated at a recorded density. The
relative population increase during that passage was calculated and
converted to population doublings.
Immunoblotting
Cells were washed twice in PBS, covered in RIPA lysis buffer
(Sviderskaya et al, 2003) and scraped off the plates. Protein
concentration was quantified using the bicinchoninic acid (BCA)
method. Protein (30mg) were electrophoresed through a 12%
SDS–polyacrylamide gel and transferred to PVDF membranes by
semi-dry blotting. Immunodetection was by enhanced chemilumi-
nescence (Amersham, Little Chalfont, UK). Antibodies used were
mouse anti-p16 (Novocastra, Newcastle, UK, or from NeoMarkers,
Newmarket, UK for the BRAF work); rabbit anti-Myc (Abcam,
Cambridge, UK), rabbit anti-p21 and rabbit anti-ERK (Santa Cruz/
Autogen Bioclear, Mile Elm, UK), and mouse anti-phospho-ERK
(Sigma). Second antibodies were appropriate HRP-conjugated
anti-mouse or rabbit Igs (Stratech, Soham, UK).
Immunostaining of lesion sections
Formalin-fixed, paraffin-embedded clinical specimens were ob-
tained from St George’s Hospital with approval from the local
Research Ethics Committee. JC or HC performed histopathological
diagnosis. Adjacent, parallel sections from the same lesions were
used for direct positional comparisons of staining for p16, Mart1,
p53, p21 and CHK2. 4-mm sections were mounted on poly-L-lysine-
coated slides. Sections were deparaffinised, rehydrated in Histo-
clear and placed in deionised water for at least 30s. Target retrieval
was by microwave heating with 0.01 M citrate buffer, pH 6.0. Slides
were rinsed with 50mM TBS wash buffer with 0.3 M NaCl and 0.1%
Tween. Immunohistochemistry used the EnVision Fast Red system
with alkaline phosphatase (DakoCytomation, Ely, UK). Antibodies
were at recommended dilutions. Anti-p16, p53 and MART-1
antibodies were from Novocastra, anti-CHK2 from Autogen
Bioclear, and anti-p21 from BD Pharmingen, Oxford, UK. Several
types of lesions including positive and negative control sections
were always immunostained simultaneously.
Immunostaining of cultured cells
Normal human neonatal epidermal melanocytes (Cascade Biolo-
gics, Mansfield, UK) and control cell lines were grown on glass
coverslips. Cultures were fixed with fresh 3.7% formaldehyde in
PBS. Permeabilisation was in 0.5% Triton X-100 in PBS.
Nonspecific sites were blocked in 1% bovine serum albumin in
PBS. The cells were exposed to anti-p16 (NeoMarkers), anti-Myc
tag (Abcam), or anti-Ki67 (Abcam) primary antibodies followed by
either anti-mouse Cy3 or anti-rabbit Cy2 secondary antibodies
(Jackson ImmunoResearch Laboratories). Cells were counter-
stained with DAPI and mounted in DABCO (Sigma).
Detection of acidic b-galactosidase (Dimri et al, 1995)
Frozen sections of benign congenital naevi of minimal diameter
10mm were used. Biopsy specimens were mounted in OCT
embedding compound and rapidly frozen in isopentane. Frozen
sections were mounted on poly-lysine-coated slides, thawed, fixed
(1min) in 1% formaldehyde in PBS, and washed twice in PBS.
They were immersed in staining solution (10% PBS, 3.95 M
K3Fe(CN)6,5 M K4Fe(CN)6,1 M MgCl2, 1mgml
 1 X-gal, pH 6.0)
for 24h at 371C. Sections were rinsed, counterstained with eosin Y,
rinsed, dehydrated, cleared and mounted. Senescent cultured
melanocytes gave a positive control.
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Figure 1 Genetic requirements for immortalisation of normal human
melanocytes. (A) Growth of a representative human melanocyte strain
(830c) following transduction of the indicated experimental or control
sequences with pBABE amphotropic retroviruses. hTERT was added two
weeks before the other sequences. Time since the second infection is
shown. Immortalisation was seen following infection with hTERT in
combination with each of the other experimental sequences. (’) HPV16-
E7þhTERT. (K) CDK4þhTERT. (m) Antisense p16þhTERT. (&)
pBABEpuroþpBABEneo. (E) pBABEpuroþpBABEpuro. Two other
human melanocyte strains, Nohm-1 (Bennett et al, 1985) and HM303CN
gave similar results (not shown). The resulting immortal melanocyte lines
were generically called Hermes 3 (from Nohm-1), Hermes 4 (from 830c)
and Hermes 5 (from HM303CN) (see (Sviderskaya et al, 2003) for Hermes
1 and 2). Growth was monitored until cells either stopped growing or
achieved at least twice the number of population doublings for that cell
strain’s normal lifespan (full curve not necessarily shown), when they were
deemed immortal. (B) Growth of 830c melanocytes following infection
with hTERT only. In 2/6 cases (one shown here), immortalisation was seen
after a lag, with hTERT only. (m) hTERT; (K) pBABEpuro. (C)
Immunoblot analysis for p16, showing negligible p16 expression in the
two normal melanocyte cultures that immortalised with hTERT only. First
lane: HM303CN melanocytes with hTERT. Second lane: 830c melanocytes
with hTERT. 3rd and 4th lanes: Nohm-1 melanocytes with hTERT and with
HPV16-E7 or CDK4 as indicated. HeLa: HeLa cells as positive control for
p16 expression.
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Immortalisation of normal human melanocytes
We previously reported that p16-deficient but not normal human
melanocytes could be immortalised by retrovirally mediated
expression of hTERT (Sviderskaya et al, 2003), suggesting that
RB1-pathway deficiency and hTERT expression were sufficient for
melanocyte immortalisation. However, this evidence was weakened
by the possibility that other genetic aberrations might be present
in the two p16-deficient melanocyte strains used (Sviderskaya et al,
2003), as these were from familial melanoma patients. We have
now tested the immortalisation requirements of three normal
human melanocyte strains. We used the following exogenous genes
to disrupt p16/RB1 signalling: an antisense p16 sequence, CDK4
cDNA overexpressed from a viral promoter, and the E7 oncogene
of human papillomavirus 16 (HPV16-E7). Melanocytes were
infected with amphotropic retroviruses containing hTERT or no
insert, and separately infected with an RB1-disrupting vector or a
control vector. Some infected cultures were initially grown with
keratinocyte feeder cells.
We previously reported that normal melanocytes could not be
immortalised using hTERT alone, even in the presence of feeder
cells (Sviderskaya et al, 2003). However, as shown in Figure 1A,
hTERT in combination with any of three approaches to disrupt the
p16/RB1 pathway could immortalise normal melanocytes. Similar
results were obtained with all three independent normal melano-
cyte strains. Cytogenetic analysis showed initially normal diploid
karyotypes for most of the immortalised cultures. Immunoblotting
of cultures infected with antisense p16 and sense CDK4 confirmed
repression of p16 expression and increased CDK4 expression,
respectively (data not shown). hTERT alone once again gave no
immortalisation in 4/6 experiments, including two cultures grown
with feeder cells. Slowly growing immortal cells were obtained in
2/6 experiments, but in both cases progressive growth started only
after a growth plateau and long lag of several months (Figure 1B),
compared to immediate growth in the presence of CDK4, antisense
p16 or HPV16-E7 as well as hTERT (Figure 1A). Moreover,
immunoblot analysis (Figure 1C) revealed virtually no p16 in
either of the two cultures that immortalised with hTERT alone. p16
is normally expressed by high-passage human melanocytes
(Bandyopadhyay et al, 2001; Bennett and Medrano, 2002), and
A
B
Figure 2 Typical expression of senescence-associated proteins in benign
compound naevi and normal epidermis. Immunostained proteins appear
red and nuclei blue (haematoxylin counterstain, except where noted).
Acidic b-galactosidase gives a blue colour, with eosin (pink) counterstain.
(A) Top and second rows, detection of melanocytic marker MART1 to
show melanocytes and for p16 in parallel sections of the same biopsy. Top
panels, low magnification of compound naevus (N), showing intense p16
immunostain (without haematoxylin). E, epidermis. Scale bar, 200mm.
Second row, higher magnification of another naevus to show detail.
Contrast slightly enhanced in right image to clarify chromatin detail. Scale
bar, 20mm. Levels of p16 expression vary, with some cells not visibly
positive. Immunostain where present is both nuclear and cytoplasmic.
Arrows: large multinucleate cells; arrowheads: large nucleoli. Third row,
parallel sections of same naevus as top panels, immunostained for p53 and
p21 as indicated. No p53 or p21 was detected. Brown material
(arrowheads) is melanin pigment. Bottom row, high magnification of
haematoxylin-stained areas of a benign compound naevus (left), showing
heterochromatic foci in nuclei (arrows), and of a VGP melanoma (right)
showing absence of such foci. Note that lesions are heterogeneous and not
all areas showed such clear differences. Contrast digitally enhanced as
sections were lightly stained. Scale bar, 20mm. (B) Top, normal adjacent
epidermis from same sections as (A) top. Scale bar, 50mm. MART1 (left)
shows distribution of normal melanocytes (arrows), which have no
detectable p16 (right). Middle and bottom, MART1 and acidic b-
galactosidase in parallel sections of a benign congenital naevus. All cells of
naevus (N) show both markers. Higher magnification (bottom) shows
some acidic b-galactosidase reactivity in whole basal epidermis (arrow-
heads), but faint compared to naevus cells. Note: frozen sections were
needed for this stain, and were available only for congenital naevi. Arrows,
melanocytes. Scale bars, 150mm (middle), 50mm (bottom).
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cultures, probably (given the long lag before growth) from a small
number of variant cells. In comparison, the cells infected with
HPV16-E7 and with overexpressed CDK4, where the entire culture
grew immediately, did not lose p16 protein (Figure 1C). This is as
expected, since these two proteins directly inhibit the p16/RB
pathway, so there would be no selection for cells lacking p16. In
summary, in 6/6 cases, hTERT expression failed to immortalise
normal melanocytes without p16/RB pathway disruption, whereas
with each of three gene combinations expressed in three
melanocyte strains, p16/RB pathway disruption combined with
hTERT did immortalise melanocytes efficiently and with no lag.
Evidence of p16-dependent senescence in benign naevi
We now used immunostaining to test expression of markers and
mediators of p16- and p53-dependent senescence in sections of
benign and malignant melanocytic lesions. p16 was clearly
detectable in 100% of benign compound naevi examined
(Figure 2A, Table 1). Typically, staining was found throughout
the lesion, although at the single-cell level, lesions were patchworks
of immunostained and unstained naevus cells (Figure 2A). As
illustrated, there was no detectable variation of p16 immunostain-
ing with depth in these lesions. p16 was nearly always nuclear as
well as cytoplasmic in naevi; nuclei stained with Fast Red as well as
haematoxylin appear purple rather than blue (Figure 2A). Naevus
cells often appeared large and sometimes multinucleate
(Figure 2A), properties seen in senescent melanocytes (Bennett
and Medrano, 2002). Prominent heterochromatic foci were often
visible in the nuclei (Figure 2A, lower left), reminiscent of the
heterochromatic foci described in senescent cells in culture (Narita
et al, 2003). These foci appeared to be uncommon in melanomas,
as illustrated for a VGP lesion (Figure 2A, lower right), although
such morphological features are variable and difficult to quanti-
tate. Importantly, no p16 was detected in normal epidermal
melanocytes (Figure 2B). The region illustrated is typical of normal
epidermis (well separated from the lesion), which we examined in
all specimens where it was present, totalling at least several
hundred melanocytes. No p16 immunostaining was found. Naevi
were then stained for acidic b-galactosidase activity, or ‘senes-
cence-associated b-galactosidase’ (Dimri et al, 1995; Sharpless and
DePinho, 2004). This appears to be expressed reliably by senescent
cells, although also by some other cells, including human cultured
melanocytes (Dimri et al, 1995). It appears to be lysosomal
b-galactosidase (Kurz et al, 2000). (This marker was studied only
in large congenital naevi, since fresh, frozen sections were required
and acquired naevi were too small for material to be spared from
routine diagnosis for freezing.) We observed strong to moderate
acidic b-galactosidase activity in 7/7 benign congenital naevi
(Figure 2B). In comparison, there was no specific staining of
normal epidermal melanocytes (Figure 2B).
Benign naevus cells thus did appear senescent, from two
molecular markers and several biological and morphological
properties (also including growth stasis). To address what type
of senescence had occurred, naevi were immunostained for p53
and p21. p21 should be expressed in p53- but not p16-dependent
senescence, while p53 levels are likely to be detectable in cells
undergoing p53-dependent senescence (Sviderskaya et al, 2003).
p21 was not detected in any of nine benign naevi, and only 1/7
showed traces of p53 (Table 1; Figure 2A). Thus the senescence in
benign melanocytic naevi is not of the p53-dependent type, and so
is either p16-dependent or some novel form of senescence.
Evidence for escape from p16-dependent senescence in
dysplastic naevi
Dysplastic naevi also all expressed some p16, although reactivity
was more patchy (Figure 3A) and half were predominantly
negative (Table 1). Interestingly, p16 was detected only in the
cytoplasm in some areas of these lesions (Figure 3A), whereas it
generally appeared both nuclear and cytoplasmic in benign naevi
(Figure 2A). Cytoplasmic p16 may sometimes be nonfunctional
(see Discussion). In culture, p16 deficiency can lead to prolonged
cell proliferation and p53-dependent senescence, as in cultured
p16-deficient melanocytes (Sviderskaya et al, 2003). A proportion
of dysplastic naevi did indeed show pockets of p53-positive cells,
sometimes with detectable p21 (Table 1; Figure 3A). p53 location
was nuclear or nuclear and cytoplasmic. Typically, however,
neither protein was observed in most of the lesion.
An atypical naevus from a p16-deficient patient: high p16
expression and possible p53-dependent senescence
Naevi from patients with biallelic p16 mutations tend to be large.
We surmised that these might exhibit p53-dependent senescence,
as confirmed for cultured melanocytes from these patients
(Sviderskaya et al, 2003). We analysed an atypical naevus from
one of the same two patients with biallelic point mutations in p16
(Huot et al, 2002) (Figure 3B). The mutant p16 was strongly
expressed in nearly all lesional cells, and not in normal adjacent
skin. This p16 protein was mostly cytoplasmic, however
(Figure 3B), consistent with its known dysfunctionality in this
patient (Huot et al, 2002). p21 and p53 were indeed expressed
widely in this naevus, generally together, although less ubiqui-
tously than p16 (Figure 3B). Pigmented melanophages (macro-
phages that have ingested melanin) and lymphocytes were often
found near dermal p53-positive cells (Figure 3B), suggestive of
melanocyte death (see Discussion).
Table 1 Differential expression of p16, p53, p21 and CHK2 in pigmented lesions of increasing malignancy
Proportion of lesions positive
p16 p53 p21 CHK2
Lesion type ++
a +
a All
a ++ + All ++ + All ++ + All
Benign compound naevi 10/11 1/11 11/11 0/7 1/7 1/7 0/9 0/9 0/9 0/8 6/8 6/8
Dysplastic naevi 5/9
b 4/9 9/9 0/7 4/7 4/7 0/7 2/7 2/7 1/6 3/6 4/6
RGP melanomas 7/14
b 7/14 14/14 0/8 6/8 6/8 0/6 6/6 6/6 2/7
c 5/7
c 7/7
c
VGP melanomas 3/14
b,d 11/14 14/14 1/8 7/8 8/8 0/8 4/8 4/8 0/8 6/8
c 6/8
c
a++: fraction of lesions that were predominantly positive (i.e. with 51–100% of cells immunostained), out of number of lesions assessed. +: fraction of lesions with detectable
immunostaining up to 50% of cells). All: all positive lesions, sum of + and ++. Lesions were scored (0, +, ++) by two independent observers, who agreed on the scores.
bSome
cytoplasmic-only reaction. Reaction generally appeared fainter in melanomas than in naevi.
cSome lesions with intensely positive areas.
dVGP melanomas that were predominantly
p16-positive were all relatively small. Columns in bold show a trend between lesion types (Po0.01, Po0.02, Po0.005, respectively, for p16, p53 and p21, by the w
2 test).
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progression
In all primary melanomas examined, we detected neither
immunoreactive p21 nor p53 in most cells, although most lesions
had a few areas with positive cells (Table 1). Likewise, in many
RGP and nearly all VGP melanomas, most areas lacked detectable
p16 (Table 1). Even where present, p16 immunoreactivity was
generally noticeably fainter and more often cytoplasmic than in
naevi (Figure 4A and B). In RGP melanomas, p53 and p21 were
often colocalised with each other, with pigmented melanocytic
cells, and with p16 (Figure 4A). Melanophages and/or lymphocytes
were again often found nearby (Figure 4A). The immunostained
cells were often large and sometimes multinucleate (Figure 4A),
features of senescent cells as already mentioned. VGP melanomas
showed similar colocalisation of the markers studied, typically at
the edges of the lesion, with the bulk of the nodule negative. Even
in these few positive areas in VGP melanomas, both p16 and p53
tended to be cytoplasmic in location (Figure 4B). In the area
shown, some lesional cells were well pigmented and also had
prominent heterochromatic foci (Figure 4B).
Differential CHK2 expression in pigmented lesions
Checkpoint kinase CHK2 is activated and mediates p53 activation
on DNA damage and in p53-dependent senescence (d’Adda di
Fagagna et al, 2003; Von Zglinicki et al, 2005). As some activated
proteins become stabilised, we surmised that CHK2 levels might
change with melanoma progression. Immunostaining for CHK2
partially supported this idea. Most lesions in each category showed
some CHK2 reaction, although generally most of each lesion was
negative, as with p53 (Figure 4C; Table 1). Intense reaction was
observed only in melanomas (Figure 4C; Table 1). CHK2
immunoreactivity was generally present in areas with p53
reactivity (Figure 4C, compare with Figures 2–4A). The naevus
from the p16-deficient patient was positive for CHK2 (not shown).
Growth inhibition and p16 elevation by oncogenic BRAF in
cultured melanocytes
We and others had speculated that senescence in moles might arise
following proliferation due to mitogenic mutations, especially the
common
V600EBRAF mutation. Accelerated senescence induced by
oncogenes has been reported in other normal human cell types.
To investigate this potential mechanism, we tested whether BRAF
sequences could induce a response resembling accelerated
senescence in normal human melanocytes. Cells were transfected
with
WTBRAF (wild-type) or
V600EBRAF sequences or a control
vector. The Nucleofection procedure gave efficient transfection
(typically around 30–40% with BRAF sequences), and effects were
assessed on the whole, unselected cultures after 5–10 days.
Findings were reproduced in four independent experiments, and
typical results are shown in Figure 5. As shown in Figure 5A,
expression of the BRAF sequences could readily be detected.
Elevation of MAPK signalling, indicated by ERK phosphorylation
relative to ERK abundance, was strong with
V600EBRAF (VE), but
not visible with
WTBRAF (WT). Cell proliferation (Ki67 labelling)
was significantly reduced in melanocytes transfected with
V600EB-
RAF but not
WTBRAF (Figure 5B). Note that there was no selection
for transfected cells, so the maximum expected growth inhibition
is 30–40% (transfection efficiency). Interestingly, expression of
p16 was significantly elevated in cultures transfected with
A
B
Figure 3 Immunostaining of senescence effectors in dysplastic naevi. (A)
lesions from normal patients. Top and middle, MART1 shows naevus cells
throughout basal epidermis in this lesion, yet there is little or no p16, little
p53 and no p21 detected in parallel sections. Scale bar, 100mm. Bottom
left, detail of p53 immunostaining in same lesion showing a few positive
nuclei (arrowheads). Scale bar, 50mm. Bottom right, detail of p16 reaction
in a different dysplastic naevus. Scale bar, 50mm. Most naevus cells here are
strongly positive for p16, yet the reaction appears generally cytoplasmic
(arrowheads: unstained nuclei). Arrow: other parts of this naevus had little
or no p16. (B) lesion from a patient lacking active p16 because of two
germline mutations. MART1 and p16 immunostaining (top) show similar
patterns: nearly all naevus cells were prominently positive for p16. Many
naevus cells are also positive for p53 and p21 (middle). Scale bar, 100mm.
Bottom left: p16 reaction is cytoplasmic only (arrowheads: unstained
nuclei). Scale bar, 30mm. Bottom right: p53-positive naevus cells in dermis,
in same lesion, surrounded by pigmented macrophages (arrows) and
lymphocytes (arrowheads). Scale bar, 50mm.
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WTBRAF, especially in individual cells
expressing
V600EBRAF relative to those expressing
WTBRAF (Figure
5A–C), whereas p21 expression was no higher with
V600EBRAF
than
WTBRAF or the empty vector (Figure 5A). Immunostaining
showed frequent nuclear expression of p16 in individual cells
expressing
V600EBRAF but not
WTBRAF (Figure 5C). Moreover,
further double immunostaining indicated mutual exclusion
between nuclear p16 and Ki67 expression among individual cells
(data not shown). Thus, the inhibition of melanocyte proliferation
by oncogenic but not
WTBRAF correlates with increased abun-
dance and nuclear location of p16, but not p21.
DISCUSSION
We report firstly that hTERT expression and p16/RB deficiency
are necessary and sufficient for immortalisation of human
melanocytes. In agreement with the extended lifespans seen in
p16-deficient melanocytes (Bennett and Medrano, 2002), this
confirms that cell senescence in cultured human melanocytes is
normally p16-dependent. Chudnovsky et al (2005) recently
described retroviral infection of melanocytes with combinations
of genes including mutant CDK4 and hTERT, and reported no
short-term alteration in proliferation in vitro, but these were
recently explanted, presenescent cultures and were not tested for
immortalisation. Melanocytes appear unusual in displaying p16-
dependent senescence in favourable culture conditions without
any apparent stress, unlike p16-dependent senescence in other cell
types (Ramirez et al, 2001). One possible residual source of ‘stress’
is the supraphysiological oxygen concentration (19%) in 90% air,
but Ramirez et al made no mention of reducing oxygen tension
when they abrogated p16-dependent senescence in keratinocytes
and mammary cells using feeder cells, and fibroblasts do not need
low oxygen to avoid p16-dependent senescence, so a cell-type
difference can still be inferred. This provides a possible rationale
for the particular relationship between p16 and melanoma, where
germline p16 mutations are predominantly associated with familial
melanoma (Hayward, 2003; Kefford et al, 2004). Findings from cell
culture cannot necessarily be extrapolated to melanocytes in the
skin, however, so it was of interest to examine proliferative lesions
in vivo directly, for possible parallels.
Cell senescence provides an attractive explanation for the
biology of moles, which first grow and then stop growing, often
remaining static for decades, as we and others have postulated
before (Bennett and Medrano, 2002; Mooi and Peeper, 2002;
Bastian, 2003; Bennett, 2003). As proposed before (Bennett, 2003;
Bennett, 2006), the initial growth stimulus seems likely to be a
mitogenic mutation, usually an activating BRAF or NRAS mutation
since these are found in around 80 and 5–15%, respectively, of
naevi (Pollock et al, 2003; Gray-Schopfer and Bennett, 2006). Here,
we report that all predicted molecular and morphological
attributes of cell senescence are found in uncultured benign naevi,
including expression of p16 and acidic b-galactosidase in all tested
lesions, markers also recently reported by Michaloglou et al
(2005). Here, we also report the presence of giant cells,
multinucleate cells and heterochromatic foci. From previous
publications, naevi show very low expression of proliferative
marker Ki67 (Healy et al, 1998), and naevus-cell cultures contain
large and multinucleate cells and grow poorly (Gilchrest et al,
1986; Halaban et al, 1986) (reviewed Bennett and Medrano (2002)).
A
B
C
Figure 4 Typical immunostaining of senescence mediators in melanomas
and naevi. (A) RGP melanomas. Top and middle: The same area of one
melanoma is positive for MART1, p16, p53 and p21, showing co-
localisation of p16, p53 and p21 in the same area, together with some
pigment. Melanophages are also seen. The unreactive cells in this area
appear to be melanoma cells; many areas of this tumour were unpigmented
and negative for all of these markers. (MART1 can be lost in advanced
melanomas). Scale bar, 100mm. Bottom left, p16-positive cells are often
large and sometimes have more than one nucleus (arrowheads). Scale bar,
60mm. Bottom right: nuclear p53 reaction in another RGP melanoma.
Again, some positive cells are multinucleate (arrowheads). Scale bar, 30mm.
(B) Typical VGP melanoma. Left: rare area of p16 expression. The positive
cells (arrows) are large and well-pigmented (melanin, brown). It is unclear
whether all pigmented cells have p16, but some have prominent nucleoli
(arrowheads). Scale bar, 30mm. Right: p53 reaction is also rare. Here, the
positive cells are again large and colocalised with pigment, and the p53 is
cytoplasmic (arrows, cells with clearly negative nuclei). Scale bar, 30mm.
(C) CHK2 expression in various lesion types. Top left: benign compound
naevus. There is nonspecific reaction and occasional stronger reaction
(arrowheads). Top right: dysplastic naevus (same area as in Figure 3A, top).
Little reaction is visible. Scale bar, 100mm. Bottom left: RGP melanoma
(same area as in A, top). Prominent CHK2 immunostain (arrowheads)
colocalises with p16, p53 and p21. Bottom right, VGP melanoma (same
area as in B), showing prominent specific reaction (arrowheads). Some
nonspecific reaction is also seen. Scale bar, 100mm.
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sp16 expression in melanocytic lesions has been studied previously,
with results largely consistent with ours (Talve et al, 1997; Keller-
Melchior et al, 1998). However, the authors did not relate p16
expression to senescence, nor examine other cell-senescence
effectors. Expression of p16 in naevi was assumed by these groups
to be normal, and was used as a comparison to report
downregulation in melanomas. Here however, we find it to be
abnormal, since crucially p16 is undetectable in epidermal
melanocytes in normal skin, and thus it is overexpressed in naevi.
Moreover, p16 expression and growth inhibition could be induced
in cultured melanocytes by expression of
V600EBRAF. This was also
recently reported by Michaloglou et al (2005), although without
any quantitation of p16. They observed growth arrest and acidic b-
galactosidase in nearly all the cells after 21 days, concluding that
the inhibited growth was a form of premature senescence. Here, we
additionally report that nuclear translocation of p16 occurred, that
WTBRAF expression did not impair growth nor increase p16
expression or nuclear location, and that p21 expression was not
correlated with the growth inhibition. Thus, if this is senescence, it
is not effected by the p53-p21 pathway. It may be either p16-
dependent or a novel form of senescence, with as-yet unknown
effector(s) in addition to p16. It seems comparable to the
premature senescence reported in other cells in response to
overexpression of oncogenes such as activated HRAS, proposed to
be a defensive response to ‘oncogenic stress’ (overstimulation of
mitogenic pathways such as the MAPK pathway) (Collado and
Serrano, 2006).
The absence of detectable p53 or p21 in most benign naevi,
using protocols that did stain these proteins in other lesions,
similarly makes it very unlikely that their senescence is p53-
dependent. Again, the senescence in naevi may be a novel form of
senescence. Otherwise it seems most likely that it is p16-dependent
senescence, since most cells in all benign naevi did express p16,
and since human melanocytes normally show p16-dependent
senescence in culture. It is unclear, however, why p16 cannot be
immunostained in all cells of benign naevi, if it mediates their
growth arrest. Several reasons seem possible. Firstly, the sensitivity
of immunostaining is limited, and the levels of p16 are clearly
variable, so it may be that p16 is actually present in all naevus cells
and is able to arrest growth at relatively low levels. Secondly, there
may be cell–cell interactions such as secretion of growth inhibitors
by senescent cells, that secondarily arrest p16-non-expressing cells
– and induce senescence marker acidic b-galactosidase, which both
we and Michaloglou et al typically observed in all cells of naevi.
Thirdly, this may be an effect of the widespread chromatin
remodelling and gene silencing that can result from high activation
of RB-family proteins (Narita et al, 2003). Cells may become so
transcriptionally inactive that p16 itself, although initially ex-
pressed, becomes silenced in some cells, growth stasis being
maintained by silencing of genes required for cell proliferation.
We proposed previously (Bennett, 2003) that dysplastic naevi
might represent escape from p16-dependent senescence and
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Figure 5 Effects of transfected BRAF sequences on cultured normal
human melanocytes. Assays were performed 10 days (A) or 5 days (B, C)
after transfection of cells. (A) Expression of growth-related proteins as
shown by immunoblotting. (NHM), normal human melanocytes, trans-
fected with the vector only (CONT, control), or with
WTBRAF (WT) or
V600EBRAF (VE) sequences. WM266-4 human melanoma cells and HeLa
cells were used as positive controls for p21 and p16 expression,
respectively. mBRAF: detection of Myc tag present on both WT and VE
transfected BRAF sequences. pERK: phospho-ERK as a marker of active
MAPK signalling. ERK: total ERK protein. (B) Counts of nuclei positive for
proliferative marker Ki67 or for p16, by immunostaining of cells transfected
with vector only (0),
WTBRAF or
V600EBRAF. Means and SEM are shown. p16
positivity is shown in both the total culture including any nontransfected
cells, and (*) as % of double-stained cells positive for exogenous BRAF
(Myc tag), that also showed nuclear p16. After only 5 days, Ki67 positivity
was significantly reduced in the total culture with
V600EBRAF (Po0.05).
Nuclear p16 expression was greater in
V600EBRAF-transfected (Po0.001)
but not
WTBRAF-transfected cells relative to control (whole culture), and in
V600EBRAF-expressing cells (over 45% positive for p16) relative to
WTBRAF-
expressing cells (Po0.001). Significance testing was by Student’s t-test. (C)
Typical examples of immunostained cells, showing nuclear p16 staining in
melanocytes expressing
V600EBRAF but not
WTBRAF. Upper label on each
panel indicates transfected sequence, lower label indicates stain. Both BRAF
proteins were immunostained with anti-Myc tag. This gave no staining in
cultures transfected with the vector only (not shown). DAPI staining
showed nuclei.
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sattainment of p53-dependent senescence (or telomeric crisis
(Sharpless and DePinho, 2004)). Here, we report that p16
expression is indeed patchy and sometimes cytoplasmic in
dysplastic naevi, but generally p53 is expressed only in a few
areas, and often without p21. Thus, dysplastic areas of naevi may
sometimes be still proliferating rather than in any kind of
senescence. We also suggested that primary melanoma cells have
emerged from senescence and immortalised (Bennett, 2003).
Previous evidence for this includes the obvious property that
melanoma cells proliferate, and the detection of telomerase activity
in most melanomas and not in naevi (Glaessl et al, 1999; Rudolph
et al, 2000). Explanted melanoma cells are not reported to senesce
(Herlyn et al, 1985), growing so readily that thousands of
melanoma cell lines exist. From immunohistochemistry of parallel
sections, we now report that senescence effectors p16, p21, p53 and
overexpressed CHK2 are undetectable in substantial regions of all
melanomas, while a few areas usually expressed all of these, often
in association with large, pigmented and/or multinucleate cells.
Such areas may represent residual senescent regions (naevus), part
of the clonal evolution of the tumours.
p16 protein at times appeared cytoplasmic-only. This
may sometimes indicate a dysfunctional, mutant protein, as it
does in the naevus from the p16-mutant patient (Huot et al, 2002),
although other factors such as other RB pathway alterations may
affect p16 location. More commonly p16 was absent from much of
a melanoma section, especially in VGP lesions; this can be
explained partly by the high rate of p16 deletion in primary
melanomas (Curtin et al, 2005), but may also involve other
mechanisms, since the said deletions are often not homozygous.
In some cases, p53-expressing lesional cells in the dermis were
surrounded by lymphocytes and melanophages. Among other
possible explanations, death of lesional melanocytes may provoke
an inflammatory reaction. This is plausible: lesional melanocytes
strongly expressing p53 are likely to be p16/RB-deficient, and
cultured p16-deficient melanocytes tend to apoptose in the absence
of keratinocytes (Bennett, 2003; Sviderskaya et al, 2003).
Strong genetic evidence that the proliferative arrest in naevi can
be p16-dependent is provided by the frequent association of
germline p16 defects with larger, more numerous and dysplastic
naevi (Gruis et al, 1995; Bennett, 2003), as well as with melanoma
susceptibility. Here, we report unusual p53 and p21 expression in a
large naevus from a patient who lacks functional p16 and whose
cells thus cannot undergo p16-dependent senescence. It is possible
that this naevus was undergoing or approaching p53-dependent
senescence, although not proven. As the p16 sequence is a
melanoma susceptibility gene (Gruis et al, 1995; Hayward, 2003),
p16 must somehow impede melanoma development. However, not
all melanoma families with p16 mutations do have abnormally
large naevi (Hayward, 2003; Kefford et al, 2004); likewise members
bearing the same p16 mutation within a single family can vary as
to whether they have large naevi (Gruis et al, 1995), which suggests
variation between humans in the contribution of p16 compared to
other genetic (or environmental) components in determining mole
size distribution. This may involve redundancy with some
functionally related molecule, as suggested (Gruis et al, 1995).
The present report together with that of Michaloglou et al (2005)
provide persuasive evidence that the growth arrest in naevi is cell
senescence. This seems to be a highly efficient barrier to
melanoma, since naevi are far more common than melanoma. As
mediators of p53-dependent senescence are not found in benign
naevi, whereas p16 is detected in 100% of these lesions and in most
cells within the lesions, it seems likely that p16 at least contributes
to establishing senescence in naevi. This provides an attractive
possible mechanism by which the p16/RB pathway could suppress
melanoma following mitogenic mutations like BRAF activation. It
was reported recently that RB pathway ablation in combination
with three other genetic alterations in human melanocytes (NRAS
activation, p53 activation and hTERT expression) is necessary and
sufficient to produce melanoma-like lesions in a reconstituted
skin-xenograft model (Chudnovsky et al, 2005), in good agreement
with our genetic model (Bennett, 2003).
There is much potential for further exploration of the possibility
of cell senescence in vivo and as a real cancer barrier. Cancers
grow progressively, but various lesions such as cysts and thyroid
adenomas show self-limiting growth. Perhaps cell senescence may
occur in many organ types following initial mutations, as
supported by recent reports from animal models (Braig et al,
2005; Collado et al, 2005). This would help to explain why p16 and
p53 are such universal tumour suppressors, and it now seems
important to investigate this possibility more widely.
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